Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial - Park, K; Tan, E H; O‘Byrne, K (Lancet Oncol, 2016)
et al.